Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

• Main Authors: Vinod Anera Balakrishna (Author), Anitha Police (Author), Rakesh Hiremath (Author), Anusha Raj (Author), Suresh P Sulochana (Author), Devaraj V Chandrasekhar (Author), Zainuddin Mohd (Author), Ravi Kanth Bhamidipati (Author), Ramesh Mullangi (Author)
• Format: Book
• Published: International Association of Physical Chemists (IAPC), 2017-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the...